WO2011044434A3 - A composition and a method of treating cns disorders and hyperpigmentation - Google Patents

A composition and a method of treating cns disorders and hyperpigmentation Download PDF

Info

Publication number
WO2011044434A3
WO2011044434A3 PCT/US2010/051934 US2010051934W WO2011044434A3 WO 2011044434 A3 WO2011044434 A3 WO 2011044434A3 US 2010051934 W US2010051934 W US 2010051934W WO 2011044434 A3 WO2011044434 A3 WO 2011044434A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
hyperpigmentation
cns disorders
hydroxychavicol
treating cns
Prior art date
Application number
PCT/US2010/051934
Other languages
French (fr)
Other versions
WO2011044434A2 (en
Inventor
Muhammed Majeed
Sarang Bani
Anjali Pandey
Susmitha Tathapudi Anand
Original Assignee
Sami Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Limited filed Critical Sami Labs Limited
Priority claimed from US12/900,727 external-priority patent/US20120088841A1/en
Publication of WO2011044434A2 publication Critical patent/WO2011044434A2/en
Publication of WO2011044434A3 publication Critical patent/WO2011044434A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a method of treating CNS disorders, particularly Alzheimer's disease. The method comprise step of administering to a subject in need thereof a therapeutically effective amount of hydroxychavicol and/or its derivatives or a composition comprising hydroxychavicol and/or its derivatives optionally along with pharmaceutically acceptable excipients. The invention also relates to use of hydroxychavicol and/or its derivatives for treating hyperpigmentation.
PCT/US2010/051934 2009-10-09 2010-10-08 A composition and a method of treating cns disorders and hyperpigmentation WO2011044434A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25010609P 2009-10-09 2009-10-09
US61/250,106 2009-10-09
US12/900,727 US20120088841A1 (en) 2010-10-08 2010-10-08 Composition and a method of treating cns disorders and hyperpigmentation
US12/900,727 2010-10-08

Publications (2)

Publication Number Publication Date
WO2011044434A2 WO2011044434A2 (en) 2011-04-14
WO2011044434A3 true WO2011044434A3 (en) 2011-08-18

Family

ID=43857406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051934 WO2011044434A2 (en) 2009-10-09 2010-10-08 A composition and a method of treating cns disorders and hyperpigmentation

Country Status (1)

Country Link
WO (1) WO2011044434A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131717A2 (en) * 2011-03-29 2012-10-04 Council Of Scientific & Industrail Research 2',3'-epoxypropyl-3.4-dihydroxy benzene and a process for the preparation thereof
TWI699215B (en) * 2018-08-03 2020-07-21 大江生醫股份有限公司 Bioactive ingredients for neuroprotection and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157204A1 (en) * 1998-04-16 2003-08-21 Enrovita A/S Novel synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157204A1 (en) * 1998-04-16 2003-08-21 Enrovita A/S Novel synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GILANI ET AL.: "Presence of cholinomimetic and acetylcholinesterase inhibitory constituents in betel nut", LIFE SCIENCES, vol. 75, no. IS. 20, 1 October 2004 (2004-10-01), pages 2377 - 2389, XP004551452, DOI: doi:10.1016/j.lfs.2004.03.035 *
JENG ET AL.: "Reactive oxygen species are crucial for hydroxychavicol toxicity toward KB epithelial cells", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 61, no. IS.1, 24 January 2004 (2004-01-24), pages 83 - 96 *
KANG ET AL.: "gamma.-Secretase Inhibitor Reduces Allergic Pulmonary Inflammation by Modulating Th1 and Th2 Responses", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 179, no. IS. 10, 15 May 2009 (2009-05-15), pages 875 - 882, XP055120487, DOI: doi:10.1164/rccm.200806-893OC *
PANDEY ET AL.: "Hydroxychavicol inhibits immune responses to mitigate cognitive dysfunction in rats", JOURNAL OF NEUROIMMUNOLOGY, vol. 226, no. 1-2, 14 September 2010 (2010-09-14), pages 48 - 58, XP027265546 *
PANDEY ET AL.: "Modulation of Th1/Th2 cytokines and inflammatory mediators by hydroxychavicol in adjuvant induced arthritic tissues,°", CYTOKINE, vol. 49, no. IS. 1, 25 September 2009 (2009-09-25), pages 114 - 121, Retrieved from the Internet <URL:Miww.ncbi.nlm.nih.gov/pubmed/19782577j> *
SCHWARZ ET AL.: "T-helper-1 and T-helper-2 Responses in Psychiatric Disorders", BRAIN, BEHAVIOR, AND IMMUNITY, vol. 15, 2001, pages 340 - 370, XP002271624, DOI: doi:10.1006/brbi.2001.0647 *

Also Published As

Publication number Publication date
WO2011044434A2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
IL264796B (en) 6,23-substituted bile acid derivatives, pharmaceutically acceptable compositions and compounds for use in a method of treating or preventing a disease
WO2011014255A8 (en) Treatment of crohn&#39;s disease with laquinimod
WO2008052044A3 (en) Use of derivatives of propofol for treating diseases associated with oxidative stress
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
MX2009010407A (en) Fluorinated derivatives of deferiprone.
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EP2091566A4 (en) Combination treatments for alzheimer&#39;s disease and similar diseases
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2008085875A3 (en) R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
WO2013085849A3 (en) Sulfate esters of noribogaine
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2011044434A3 (en) A composition and a method of treating cns disorders and hyperpigmentation
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822748

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 10822748

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE